240 Ribosomal protein TL5/L25 C-terminal domain-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 17 | 11.1 | 1.53× | q = 0.04 | |
| Nucleosides, nucleotides, and analogues | 0 | 6.3 | 0 | q = 3.3e-3 | |
| Lipids and lipid-like molecules | 4 | 2.5 | 1.58× | not tested | |
| Homogeneous non-metal compounds | 2 | 4.9 | 0.41× | not tested | |
| Organic oxygen compounds | 1 | 4.5 | 0.22× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
No DrugBank compounds are annotated on this group's domains.
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 400 |
| MGmetal | MAGNESIUM ION | 248 |
| 1N7 | CHAPSO | 28 |
| 4QM | (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-pentan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol | 5 |
| OHX | osmium (III) hexammine | 4 |
| CL | CHLORIDE ION | 3 |
| CDmetal | CADMIUM ION | 2 |
| IOD | IODIDE ION | 2 |
| 6O1 | Evernimicin | 1 |
| NAmetal | SODIUM ION | 1 |